The article discusses the ongoing struggle of patients denied access to experimental cancer treatments, urging them to draw parallels with the historical fight by AIDS activists in the 1980s.

It highlights how those activists successfully pressured pharmaceutical companies through protests and advocacy, leading to the Emergency Drug Release Program.

The piece argues that modern patients and healthcare providers should similarly challenge the current Special Access Program to push for compassionate access to unapproved drugs.It emphasizes that terminally ill patients should have autonomy over their treatment choices, even if it involves accepting certain risks.

The author calls for collaboration between doctors, patients, and regulators to pressure American pharmaceutical firms to provide life-saving medications despite regulatory hurdles.The piece underscores the ethical imperative of prioritizing patient needs over bureaucratic inertia in medical decision-making.